NCT00511914

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture, Using the Strain Composition 2007/2008, When Administered to Adult and Elderly Subjects

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 135 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell culture, using the strain composition 2007/2008, when administered to adult and elderly subjects

Conditions

• Seasonal Influenza Vaccine

Interventions

Type	Name	Description
BIOLOGICAL	cTIV	One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle

Timeline

• Start date: 2007-07-01
• Primary completion: 2007-08-01
• Completion: 2007-08-01
• First posted: 2007-08-06
• Last updated: 2013-01-24
• Results posted: 2013-01-17

Locations

2 sites across 1 country: Germany